Journal of Clinical Oncology, Vol 21, Issue 2
(January), 2003: 334-341
© 2003 American Society for Clinical Oncology
Osteosarcoma of the Pelvis: Experience of the Cooperative Osteosarcoma Study Group
Toshifumi Ozaki,
Silke Flege,
Matthias Kevric,
Norbert Lindner,
Rainer Maas,
Günter Delling,
Rudolf Schwarz,
Arthur R. von Hochstetter,
Mechthild Salzer-Kuntschik,
Wolfgang E. Berdel,
Heribert Jürgens,
G. Ulrich Exner,
Peter Reichardt,
Regine Mayer-Steinacker,
Volker Ewerbeck,
Rainer Kotz,
Winfried Winkelmann,
Stefan S. Bielack
From the Departments of Orthopaedic Surgery, Pediatric Haematology and Oncology, and Medicine/Hematology and Oncology, Westfälische Wilhelms-University, Münster; Department of Orthopaedic Surgery, University of Heidelberg, Heidelberg; Departments of Bone Pathology, Pediatric Oncology, and Radiotherapy, University Hospital Hamburg-Eppendorf, Robert-Rössle-Klinik, Berlin; Cancer Center, Ulm, Germany; Department of Orthopaedics, Balgrist, Department of Pathology, University Hospital of Zürich, Switzerland; and Department of Orthopedics, Institute of Pathological Anatomy, University of Vienna, Vienna, Austria.
Address reprint requests to Toshifumi Ozaki, MD, Department of Orthopaedic Surgery, Okayama University Medical School, Okayama 700-8558, Japan; email: tozaki{at}md.okayama-u.ac.jp.
Purpose: To define patients and tumor characteristics as well as therapy results, patients with pelvic osteosarcoma who were registered in the Cooperative Osteosarcoma Study Group (COSS) were analyzed.
Patients and Methods: Sixty-seven patients with a high-grade pelvic osteosarcoma were eligible for this analysis. Fifteen patients had primary metastases. All patients received chemotherapy according to COSS protocols. Thirty-eight patients underwent limb-sparing surgery, 12 patients underwent hemipelvectomy, and 17 patients did not undergo definitive surgery. Eleven patients received irradiation to the primary tumor site: four postoperatively and seven as the only form of local therapy.
Results: Local failure occurred in 47 of all 67 patients (70%) and in 31 of 50 patients (62%) who underwent definitive surgery. Five-year overall survival (OS) and progression-free survival rates were 27% and 19%, respectively. Large tumor size (P = .0137), primary metastases (P = .0001), and no or intralesional surgery (P < .0001) were poor prognostic factors. In 30 patients with no or intralesional surgery, 11 patients with radiotherapy had better OS than 19 patients without radiotherapy (P = .0033). Among the variables, primary metastasis, large tumor, no or intralesional surgery, no radiotherapy, existence of primary metastasis (relative risk [RR] = 3.456; P = .0009), surgical margin (intralesional or no surgical excision; RR = 5.619; P < .0001), and no radiotherapy (RR = 4.196; P = .0059) were independent poor prognostic factors.
Conclusion: An operative approach with wide or marginal margins improves local control and OS. If the surgical margin is intralesional or excision is impossible, additional radiotherapy has a positive influence on prognosis.
Supported in part by a grant from the Alexander von Humboldt Foundation. The Cooperative Osteosarcoma Study Group studies are supported by Deutsche Krebshilfe.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. MURAMATSU, K. IHARA, Y. TANI, R. IWANAGA, and T. TAGUCHI
Reconstruction of Periacetabular Bone Tumor by Vascularized Fibula Graft and Irradiated Autograft
Anticancer Res,
May 1, 2009;
29(5):
1669 - 1673.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. S. Hosalkar and J. P. Dormans
Surgical Management of Pelvic Sarcoma in Children
J. Am. Acad. Ortho. Surg.,
July 1, 2007;
15(7):
408 - 424.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Hosono, Y. Nishida, W. Knudson, C. B. Knudson, T. Naruse, Y. Suzuki, and N. Ishiguro
Hyaluronan Oligosaccharides Inhibit Tumorigenicity of Osteosarcoma Cell Lines MG-63 and LM-8 in Vitro and in Vivo via Perturbation of Hyaluronan-Rich Pericellular Matrix of the Cells
Am. J. Pathol.,
July 1, 2007;
171(1):
274 - 286.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Delloye, X. Banse, B. Brichard, P.-L. Docquier, and O. Cornu
Pelvic Reconstruction with a Structural Pelvic Allograft After Resection of a Malignant Bone Tumor
J. Bone Joint Surg. Am.,
March 1, 2007;
89(3):
579 - 587.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T.-a. Matsui, Y. Sowa, T. Yoshida, H. Murata, M. Horinaka, M. Wakada, R. Nakanishi, T. Sakabe, T. Kubo, and T. Sakai
Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells
Carcinogenesis,
September 1, 2006;
27(9):
1768 - 1777.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. M. Anderson, G. A. Wiseman, L. Erlandson, V. Rodriguez, B. Trotz, S. A. Dubansky, and K. Albritton
Gemcitabine Radiosensitization after High-Dose Samarium for Osteoblastic Osteosarcoma
Clin. Cancer Res.,
October 1, 2005;
11(19):
6895 - 6900.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Kempf-Bielack, S. S. Bielack, H. Jurgens, D. Branscheid, W. E. Berdel, G. U. Exner, U. Gobel, K. Helmke, G. Jundt, H. Kabisch, et al.
Osteosarcoma Relapse After Combined Modality Therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS)
J. Clin. Oncol.,
January 20, 2005;
23(3):
559 - 568.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Marina, M. Gebhardt, L. Teot, and R. Gorlick
Biology and Therapeutic Advances for Pediatric Osteosarcoma
Oncologist,
July 1, 2004;
9(4):
422 - 441.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Sonmezer and K. Oktay
Fertility preservation in female patients
Hum. Reprod. Update,
May 1, 2004;
10(3):
251 - 266.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|